Solventum (SOLV) to Release Quarterly Earnings on Tuesday

Solventum (NYSE:SOLV) is expected to announce its Q1 2026 results after the market closes on Tuesday, May 5th. Analysts expect the company to announce earnings of $1.35 per share and revenue of $1.9674 billion for the quarter. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 4:30 PM ET.

Solventum (NYSE:SOLV) last released its quarterly earnings data on Thursday, February 26th. The company reported $1.57 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.07. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The business had revenue of $2 billion for the quarter, compared to analyst estimates of $1.96 billion. During the same quarter last year, the firm earned $1.41 EPS. Solventum’s quarterly revenue was down 3.7% compared to the same quarter last year. On average, analysts expect Solventum to post $7 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Solventum Trading Up 0.9%

Solventum stock traded up $0.60 during midday trading on Monday, hitting $67.23. 575,756 shares of the stock were exchanged, compared to its average volume of 1,196,543. The company has a fifty day simple moving average of $67.99 and a two-hundred day simple moving average of $74.53. Solventum has a 52 week low of $62.38 and a 52 week high of $88.20. The stock has a market capitalization of $11.66 billion, a PE ratio of 7.60, a P/E/G ratio of 1.09 and a beta of 0.59. The company has a quick ratio of 0.89, a current ratio of 1.23 and a debt-to-equity ratio of 1.00.

Insiders Place Their Bets

In related news, Director Amy Mcbride Wendell purchased 1,475 shares of the business’s stock in a transaction on Tuesday, March 10th. The shares were purchased at an average price of $68.03 per share, with a total value of $100,344.25. Following the completion of the purchase, the director owned 5,039 shares in the company, valued at $342,803.17. This represents a 41.39% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.24% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. State Street Corp raised its holdings in shares of Solventum by 2.0% in the fourth quarter. State Street Corp now owns 6,344,761 shares of the company’s stock valued at $502,759,000 after purchasing an additional 124,490 shares during the last quarter. Boston Partners raised its holdings in shares of Solventum by 26.1% in the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after purchasing an additional 959,543 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Solventum by 3.4% in the fourth quarter. Invesco Ltd. now owns 2,930,010 shares of the company’s stock valued at $232,174,000 after purchasing an additional 96,236 shares during the last quarter. Morgan Stanley raised its holdings in shares of Solventum by 13.2% in the fourth quarter. Morgan Stanley now owns 1,660,906 shares of the company’s stock valued at $131,610,000 after purchasing an additional 193,154 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of Solventum by 3.6% in the third quarter. Northern Trust Corp now owns 1,596,490 shares of the company’s stock valued at $116,544,000 after purchasing an additional 56,146 shares during the last quarter.

Analyst Upgrades and Downgrades

SOLV has been the topic of several recent analyst reports. Wells Fargo & Company raised shares of Solventum to a “hold” rating in a research note on Wednesday, March 18th. Stifel Nicolaus lifted their price objective on shares of Solventum from $88.00 to $105.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. Weiss Ratings reissued a “hold (c)” rating on shares of Solventum in a research note on Tuesday, January 27th. KeyCorp reduced their price objective on shares of Solventum from $99.00 to $92.00 and set an “overweight” rating on the stock in a research note on Monday, April 27th. Finally, BTIG Research reissued a “buy” rating and set a $100.00 price objective on shares of Solventum in a research note on Friday, February 27th. Seven research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $89.45.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.